MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2

Zhou,Fenmei; Chen,Juan; Wang,Hairong

doi:10.3892/ol.2016.5204

MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2

Authors:
- Fenmei Zhou
- Juan Chen
- Hairong Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China, Huai'an Maternal and Child Healthcare Center, Huai'an, Jiangsu 223302, P.R. China
Published online on: September 29, 2016 https://doi.org/10.3892/ol.2016.5204
Pages: 3926-3932
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miRNA or miR)-298 has been reported to be downregulated and to modify the expression of the polycomb protein enhancer of zeste 2 (EZH2) in recurrent epithelial ovarian cancer (EOC). To date, no functional evidence of a miR-298-EZH2 axis in EOC has been documented. The present study aimed to investigate the associations of miR‑298 and/or EZH2 expression with clinicopathological features of EOC patients, and revealed their roles in cell motility based on EOC cell lines. Reverse transcription-quantitative polymerase chain reaction was performed to detect the expression levels of miR‑298 and EZH2 messenger RNA in human EOC tissues and cell lines. Wound healing and transwell assays were performed to determine the function of the miR‑298‑EZH2 axis on cell migration and invasion, respectively. Compared with normal tissues, miR‑298 expression was significantly downregulated, while EZH2 expression was significantly upregulated, in human EOC tissues (both P=0.001). In addition, miR‑298 downregulation and EZH2 upregulation were significantly associated with high clinical stage (both P=0.01) and pathological grade (both P=0.02) of EOC patients. Furthermore, the ectopic expression of miR‑298 could efficiently inhibit cell migration and invasion. Notably, the overexpression of EZH2 could restore the cell migration and invasion abilities suppressed by miR‑298. Our data offer convincing evidence that the dysregulation of the miR‑298‑EZH2 axis may be important in tumor progression of EOC patients. The present study also confirmed a tumor‑suppressive role of miR‑298 in modulating EOC cell motility by regulating the expression of EZH2, implying its potential as a novel miRNA‑based therapeutic target for the treatment of human EOC.

View Figures

View References

1	Vargas-Hernández VM, Moreno-Eutimio MA, Acosta-Altamirano G and Vargas-Aguilar VM: Management of recurrent epithelial ovarian cancer. Gland Surg. 3:198–202. 2014.PubMed/NCBI
2	Xu L, Cai J, Yang Q, Ding H, Wu L, Li T and Wang Z: Prognostic significance of several biomarkers in epithelial ovarian cancer: A meta-analysis of published studies. J Cancer Res Clin Oncol. 139:1257–1277. 2013. View Article : Google Scholar : PubMed/NCBI
3	Yeh YM, Chuang CM, Chao KC and Wang LH: MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer. 133:867–878. 2013. View Article : Google Scholar : PubMed/NCBI
4	Huang L, Lv W and Zhao X: CD24 as a molecular marker in ovarian cancer: A literature review. Cancer Transl Med. 2:29–32. 2016. View Article : Google Scholar
5	Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
6	Minig L, Otaño L, Diaz-Padilla I, Gallego R Alvarez, Patrono MG and de Bernabé J Valero: Therapeutic management of epithelial ovarian cancer during pregnancy. Clin Transl Oncol. 15:259–264. 2013. View Article : Google Scholar : PubMed/NCBI
7	Hata A and Lieberman J: Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal. 8:re32015. View Article : Google Scholar : PubMed/NCBI
8	Shen J and Hung MC: Signaling-mediated regulation of MicroRNA processing. Cancer Res. 75:783–791. 2015. View Article : Google Scholar : PubMed/NCBI
9	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
10	Zaman MS, Maher DM, Khan S, Jaggi M and Chauhan SC: Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
11	Mansoori B, Mohammadi A, Shirjang S and Baradaran B: Micro-RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy. Cell Mol Biol (Noisy-le-grand). 61:1–10. 2015.PubMed/NCBI
12	Wang YQ, Guo RD, Guo RM, Sheng W and Yin LR: MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas. J Cell Biochem. 114:1464–1473. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zhang H, Wang Q, Zhao Q and Di W: MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J Ovarian Res. 6:842013. View Article : Google Scholar : PubMed/NCBI
14	Wu H, Xiao Z, Wang K, Liu W and Hao Q: MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. Biochem Biophys Res Commun. 441:693–700. 2013. View Article : Google Scholar : PubMed/NCBI
15	Gui T, Bai H, Zeng J, Zhong Z, Cao D, Cui Q, Chen J, Yang J and Shen K: Tumor heterogeneity in the recurrence of epithelial ovarian cancer demonstrated by polycomb group proteins. Onco Targets Ther. 7:1705–1716. 2014.PubMed/NCBI
16	Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Peregrin I, Mendizabal E and Ortiz-Quintana L: International Federation of Gynecology and Obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: Estimation of survival in patients with node-positive epithelial ovarian cancer. Int J Gynecol Cancer. 25:49–54. 2015. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Zhang Q, Padi SK, Tindall DJ and Guo B: Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis. 5:e14862014. View Article : Google Scholar : PubMed/NCBI
19	Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Munkarah AR, et al: MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf1/cip1). Pharm Res. 28:3079–3090. 2011. View Article : Google Scholar : PubMed/NCBI
20	Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G and An HJ: miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma. Cancer Lett. 356:937–945. 2015. View Article : Google Scholar : PubMed/NCBI
21	Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, Chi KN, Marshall VR, Tilley WD and Butler LM: Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 131:652–661. 2012. View Article : Google Scholar : PubMed/NCBI
22	Bao L, Hazari S, Mehra S, Kaushal D, Moroz K and Dash S: Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 180:2490–2503. 2012. View Article : Google Scholar : PubMed/NCBI
23	Han Li C and Chen Y: Targeting EZH2 for cancer therapy: Progress and perspective. Curr Protein Pept Sci. 16:559–570. 2015. View Article : Google Scholar : PubMed/NCBI
24	Verma SK: Inhibition of the histone lysine methyltransferase EZH2 for the treatment of cancer. Curr Top Med Chem. 15:714–719. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li LY: EZH2: Novel therapeutic target for human cancer. Biomedicine (Taipei). 4:12014. View Article : Google Scholar : PubMed/NCBI
26	Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V and Cristofanilli M: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
27	Yang YA and Yu J: EZH2, an epigenetic driver of prostate cancer. Protein Cell. 4:331–341. 2013. View Article : Google Scholar : PubMed/NCBI
28	Li T, Cai J, Ding H, Xu L, Yang Q and Wang Z: EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1. Cancer Biol Ther. 15:271–278. 2014. View Article : Google Scholar : PubMed/NCBI
29	Liu L, Guo J, Yu L, Cai J, Gui T, Tang H, Song L, Wang J, Han F, Yang C, et al: miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol. 35:12619–12626. 2014. View Article : Google Scholar : PubMed/NCBI
30	Martin TA, Ye L, Sanders AJ, Lane J and Jiang WG: Cancer invasion and metastasis: Molecular and cellular perspectiveMetastatic Cancer: Clinical and Biological Perspectives. Jandial R: Madame Curie Bioscience Database. Landes Bioscience; Austin, TX: pp. 2000–2013